Dynavax Technologies | DVAX - Текущие активы



Текущие активы Изменить Дата
AbbVie USD 33.53B 4.47B 2026-03
Adma Biologics USD 511.17M 44.66M 2026-03
Agenus USD 95.28M 38.15M 2026-03
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
TG Therapeutics USD 1.09B 456.2M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03